Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Celestica Inc (CLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Celestica Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Celestica Inc trades at $350.85 (market cap $41.29B). The key difference: Alnylam Pharmaceuticals, Inc. and Celestica Inc are close in size by market cap, and Celestica Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CLS | |
|---|---|---|
Market Cap | $39.89B | $41.29B |
Sector | Health | Technology |
52-Week High | $491.22 | $472.40 |
52-Week Low | $278.09 | $156.91 |
Enterprise Value | $38.15B | $41.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CLS trades at $359.85, up 1.43% today, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with a 52.45% ROE and 6.95% net margin, supported by positive analyst sentiment and a $440.10 consensus price target. Recent leadership changes and raised revenue guidance to $19 billion highlight growth prospects in AI and cloud infrastructure.
Outlook remains positive driven by AI demand and earnings beats, but high valuation multiples (P/E 43.62) and competitive pressures pose risks. Investors should monitor Q2 2026 results on July 27, 2026, for confirmation of growth trajectory amid margin challenges noted by analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
